54 results about "Bazedoxifene acetate" patented technology

The present invention relates to methods of preparing polymorphic Form A of bazedoxifene acetate and polymorphic Form A prepared by such methods.

A novel process is described for the preparation of pharmaceutically useful compounds such as 1-{4-[2-(azepan-1-yl)ethoxy]benzyl}-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol acetic acid commonly known as bazedoxifene acetate of the formula-1 using 2-(4-{[5-(benzyloxy)-2-[4-(benzyloxy)phenyl]-3-methyl-1H-indol-1-yl]methyl}phenoxy)ethyl-4-methylbenzenzene-1-sulfonate (formula 2a)

Efficient processes for the synthesis of pharmaceutically useful compounds such as (1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol acetic acid commonly known as bazedoxifene acetate (Formula IX) using cyanomethoxybenzyl halides of Formula III, where X=Halogens e.g., Cl, F, Br, I; G=Any electron donating or electron withdrawing substituent.

The invention belongs to the field of medicinal chemistry, and discloses a preparation method of bazedoxifene acetate. The method comprises the following steps: carrying out condensation reaction on a compound I and a compound II in an organic solvent under an alkaline condition, so as to obtain an intermediate III; hydrolyzing and salifying the intermediate III, so as to obtain the target compound, namely bazedoxifene acetate (TM). By adopting the method, the productivity and the quality of bazedoxifene acetate can be obviously improved.

The invention belongs to the technical field of chemical pharmacy and relates to a preparation method of a bazedoxifene acetate crystal form A. The preparation method of the bazedoxifene acetate crystal form A comprises the following steps: step 1, in the presence of palladium/carbon serving as a catalyst, dissolving hexamethyleneimine benzyloxy benzpyrole and ammonium formate in a benign organic solvent to have reaction; step 2, after the reaction is finished completely, filtering the palladium on activated carbon, cooling the filtrate, adding acetic acid and a toxic inorganic solvent, stirring, crystallizing, filtering and drying to obtain a crude crystal form A product; step 3, under the protection and presence of inert gas, dissolving the crude crystal form A product in the benign organic solvent, heating and dissolving; step 4, thermally filtering the solution, cooling the filtrate, dropwise adding the toxic inorganic solvent and crystallizing; step 5, after the crystallization is ended, filtering the solution and drying the solid to obtain the bazedoxifene acetate crystal form A.

A preparation method of bazedoxifene acetate is characterized by including the following steps: (1) performing a reaction by mixing and suspending a compound represented in the formula (A), ammonium formate or cyclohexadiene, and a palladium-carbon catalyst in an organic solvent, reaction terminal being detected with TLC or HPLC; (2), filtering and washing a reaction product, adding acetic acid with stirring, and filtering and drying the mixture to prepare the bazedoxifene acetate. The invention also provides a preparation method of a bazedoxifene acetate crystal form A. The preparation method is free of hydrogen and avoids usage of special devices, such as a hydrogenation kettle, while a safe hydrogen donor is employed, so that the method can be carried out even with a common reaction kettle and a reaction workshop, thereby reducing dangerousness of the synthesis and building and operation cost of a special device workshop. The preparation method of the crystal form A, compared with the prior art, is simple in operation, is free of a crystal seed for inducing crystallization, is high in crystal form purity and is simple in solvent system which can be recycled and reused.

The invention relates to a method for preparing an impurity A having the purity of more than 97% from a bazedoxifene raw material, can be applied in research of reference substances and belongs to the field of medicine.

The invention discloses a preparation method of bazedoxifene acetate polycrystalline type B. Bazedoxifene free alkali and glacial acetic acid are taken as raw materials and salified to obtain the bazedoxifene acetate polycrystalline type B. The operation conditions of the preparation process are simple and do not need to be carried out under the protection of inert gas; no antioxidant is used in the preparation process; the yield and purity of the prepared product are high, and therefore the product is suitable for industrial production.

The invention discloses an industrial production method for bazedoxifene acetate. The production method comprises the following steps: taking p-hydroxy benzaldehyde as a starting material, substituting with chloracetyl-hexamethyleneimine, reducing with borohydride and chlorinating with a chlorinating agent to obtain a compound 4; reacting the compound 4 with 5-(benzyloxy)-2-(4-(benzyloxy)phenyl)-3-methyl-1H-indole to obtain a compound 5; and carrying out debenzylation to obtain a compound 6, and salifying with acetic acid to obtain a target compound which is the bazedoxifene acetate. The defective workmanship of preparation in the prior art is solved, the used reagent is low in cost and easy to obtain, environmental pollution is small, safety is high, an operation process is simple, and thus, the bazedoxifene acetate is suitable for being produced industrially.

The invention discloses a bazedoxifene acetate composition with excellent properties. The composition comprises bazedoxifene acetate, polyethylene glycol (PEG) 6000-8000 and vitamin E tocopherol polyethylene glycol succinate (TPGS), wherein a solid solution and/or solid sol is formed by polyethylene glycol (PEG) 6000-8000 and vitamin E TPGS, and bazedoxifene acetate is dispersed into the solid solution and/or solid sol. The composition is high in chemical stability and medicine release speed.

The invention discloses a bazedoxifene acetate emplastrum preparation and a preparation method thereof. According to the preparation method, transdermal emplastrum is prepared from bazedoxifene acetate micro-emulsion, and is divided into four layers, namely an anti-adhesive layer, an adhesive layer, a lining layer and a drug-storage layer, wherein the effective component is bazedoxifene acetate micro-emulsion, and is prepared from bazedoxifene acetate serving as an active component, polysorbate 80 serving as a surfactant, propylene glycol serving as a cosurfactant, purified water or distilled water and the like. Except the effective component, the emplastrum also comprises a non-polar polymer, a plasticizer, a tackifier, a transdermal enhancer and an antioxidant. Compared with the existing preparations, such as tablets, the bazedoxifene acetate emplastrum has the prominent advantages of durable drug effect, safety and low toxicity and accurate administration dosage, is convenient to use, and is simple and sanitary.

The invention discloses a bazedoxifene (Viviant) acetate composition and a bazedoxifene acetate film-coated tablet preparation method, and relates to the technical field of medicines. The bazedoxifene acetate composition comprises the following components by weight of 20-26 parts of bazedoxifene acetate, 250-350 parts of a filling agent, 30-50 parts of an adhesive, 8-15 parts of a disintegrating agent, 3-6 parts of an antioxidant, 2-6 parts of a flow aid, 0.1-0.5 part of a lubricant, 1-3 parts of a wetting agent, and a proper amount of a purified water solvent, wherein bazedoxifene acetate is a BCS II type medicine, and the particle size D90 is 30 microns; the antioxidant is vitamin C; and the filling agent is composed of lactose and microcrystalline cellulose, and the ratio of the lactose to the microcrystalline cellulose is 1: 2-2: 1 according to the weight fraction. The fluidized bed granulation technology adopting the process for preparation is simple in process, lower in cost and easy for industrial production.

The invention discloses a bazedoxifene acetate capsule which is used for preventing the osteoporosis of postmenopausal women. The capsule is convenient to carry and take, and compared with a tablet and a pill, the bazedoxifene acetate capsule is dispersed in stomachs and dissolved out more quickly, and takes the effect more quickly. Meanwhile, the invention further discloses a preparation method of the bazedoxifene acetate capsule. Compared with a common capsule granulating method, capsule grains prepared by the preparation method can improve the stability of drugs and preparations of the drugs effectively.

The invention discloses a preparation method of a pure acetic acid bazedoxifene crystal form A. The preparation method comprises the following process steps of firstly, under the condition of using palladium carbon as a catalyst, dissolving raw materials into a good organic solvent, and introducing hydrogen to react to a non-raw material point; after reaction is completed, filtering to remove the palladium carbon, cooling filtrate, adding acetic acid and a poor organic solvent, stirring, crystallizing, filtering, and drying, so as to obtain a crude product of the crystal form A. The preparation method has the advantages that the technology is simple, the production efficiency is high, and the preparation cost of the pure acetic acid bazedoxifene crystal form A is effectively reduced.

The invention discloses a bazedoxifene acetate sustained release preparation with excellent performance and a preparation process thereof. The preparation is a sustained release dropping pill, which comprises the following components in percentage by weight: 1-25 percent of bazedoxifene acetate, 40-70 percent of hydrophobic dropping pill matrix, and 5-40 percent of hydrophilic matrix. The sustained release dropping pill has a higher chemical stability, physical stability (low-crystal form conversion rate) and in-vivo drug-release behavior (higher bioavailability and smooth and durable plasma concentration).

The invention discloses a crystal form of bazedoxifene L-lactate. An X-ray powder diffraction pattern displayed by the crystal form has peaks of the following spacing values: 21.66 angstroms, 19.40 angstroms, 18.94 angstroms, 18.66 angstroms, 18.36 angstroms, 18.00 angstroms, 16.84 angstroms, 16.34 angstroms, 15.22 angstroms, 12.44 angstroms, 12.32 angstroms, 12.12 angstroms, and 9.38 angstroms. According to the crystal form of the bazedoxifene L-lactate, disclosed by the invention, the water solubility is much higher than that of various crystal forms (A, B, C and D) of bazedoxifene acetate;crude drugs for preparing tablets do not need to be micronized and the crystal form has good stability; the risk of crystal form transformation does not occur in a medicine preparation process.